BackLakeShore Biopharma Co Overview

LakeShore Biopharma Co EBIT

Latest ebit for YS: $-360M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$93.16M

As of Mar 31, 2024

Annual EBIT (TTM)

-$358.09M

Trailing 12 months ending Mar 31, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

LakeShore Biopharma Co (YS) FAQ

LakeShore Biopharma Co (YS) currently reports a EBIT of $-360M as of March 2024. That is below the sector sector average of $2.4T. Use the charts on this page to explore LakeShore Biopharma Co's EBIT history and peer comparisons.

LakeShore Biopharma Co's EBIT of $-360M is lower than the its sector sector average of $2.4T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

LakeShore Biopharma Co reported $-360M in EBIT as of March 2024. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-360M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.4T. From there, open related valuation or income-statement pages for LakeShore Biopharma Co, and consider following YS for alerts when major investors trade the stock.